Abstract
Background
Transrectal ultrasound-guided prostate biopsy (TRUSPB) is widely used to diagnose prostate cancer (PCa). The aim of this study was to evaluate the risk of multi-factorial complications (febrile genitourinary tract infection (GUTI), rectal bleeding, and urinary retention) after TRUSPB.
Methods
N = 2053 patients were Japanese patients undergoing transrectal or transperineal TRUSPB for suspicious of PCa. To assess risk of febrile GUTI adequately, the patients were divided into four groups: low-risk patients before starting a rectal culture, low-risk patients after starting a rectal culture, high-risk patients, and patients undergoing transperineal TRUSPB. Furthermore, to identify risk of rectal bleeding and urinary retention, patients were divided into transrectal and transperineal group.
Results
Febrile GUTI significantly decreased owing to risk classification. The frequency of rectal bleeding was 1.43% (transrectal: 25/1742), while it did not happen in transperineal group. The patients with rectal bleeding had a significantly lower body mass index (BMI) (P < 0.01). The frequency of urinary retention was 5.57% (transrectal: 97/1742), while it did not happen in transperineal group. The patients with urinary retention had a significantly higher prostate-specific antigen (PSA) (P = 0.01) in transrectal group.
Conclusions
Risk classification, rectal swab culture, and selected antimicrobial prophylaxis for transrectal TRUSPB were extremely effective to reduce the risk of febrile GUTI. Furthermore, lower BMI and higher PSA were novel clinical predictors for rectal bleeding and urinary retention, respectively. When urologists perform transrectal TRUSPB to their patients, they can correctly understand and explain each complication risk to their patients based on these novel risk factors.
Similar content being viewed by others
References
Utsumi T, Oka R, Endo T et al (2015) External validation and comparison of two nomograms predicting the probability of Gleason sum upgrading between biopsy and radical prostatectomy pathology in two patient populations: a retrospective cohort study. Jpn J Clin Oncol 45:1091–1095
Ito K, Furuta A, Kido A et al (2020) Detectability of prostate cancer in different parts of the gland with 3-Tesla multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Int J Clin Oncol 25:732–740
Tohi Y, Kato T, Matsumoto R et al (2020) The impact of complications after initial prosate biopsy on repeat protocol biopsy acceptance rate. Results from the Ptostate Cancer Research International: Active Surveillance JAPAN study. Int J Clin Oncol 26:956–970
Teoh JYC, Hirai HW, Ho JMW et al (2019) Global incidence of prostate cancer in developing and developed countries with changing age structures. PLoS ONE 14:1–9
Ding XF, Luan Y, Lu SM et al (2020) Risk factors for infection complications after transrectal ultrasound-guided transperineal prostate biopsy. World J Urol (in press)
Togo Y, Kubo T, Taoka R et al (2014) Occurrence of infection following prostate biopsy procedures in Japan Japanese Research Group for Urinary Tract Infection (JRGU)—a multi-center retrospective study. J Infect Chemother 20:232–237
Hiyama Y, Takahashi S, Uehara T et al (2019) Selective culture of Escherichia coli to prevent infective complications of transrectal ultrasound-guided prostate biopsy: clinical efficacy and analysis of characteristics of quinolone-resistant Escherichia coli. Int J Urol 26:655–660
Derin O, Fonseca L, Sanchez-Salas R et al (2020) Infectious complications of prostate biopsy: winning battles but not war. World J Urol 38:2743–2753
Xiang J, Yan H, Li J, Wang X et al (2019) Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis. World J Surg Oncol 17:1–11
Togo Y, Yamamoto S (2017) Prevention of infectious complications after prostate biopsy procedure. Int J Urol 24:486–492
Cheng KC, Lam WC, Chan HC et al (2019) Emergency attendances and hospitalisations for complications after transrectal ultrasound-guided prostate biopsies: a five-year retrospective multicentre study. Hong Kong Med J 25:349–355
Ivan SJ, Sindhwani P (2018) Comparison of guideline recommendations for antimicrobial prophylaxis in urologic procedures: variability, lack of consensus, and contradictions. Int Urol Nephrol 50:1923–1937
Yasuda M, Nakane K, Yamada Y et al (2014) Clinical effectiveness and safety of tazobactam/piperacillin 4.5 g for the prevention of febrile infectious complication after prostate biopsy. J Infect Chemother 20:631–634
Shen PF, Zhu YC, Wei WR et al (2012) The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis. Asian J Androl 14:310–315
Loeb S, Vellekoop A, Ahmed HU et al (2013) Systematic review of complications of prostate biopsy. Eur Urol 64:876–892
Quinlan MR, Bolton D, Casey RG (2018) The management of rectal bleeding following transrectal prostate biopsy: a review of the current literature. J Can Urol Assoc 12:E146–E153
Lo KL, Chui KL, Leung CH et al (2019) Outcomes of transperineal and transrectal ultrasound-guided prostate biopsy. Hong Kong Med J 25:209–215
Borghesi M, Ahmed H, Nam R et al (2017) Complications after systematic, random, and image-guided prostate biopsy [figure presented]. Eur Urol 71:353–365
Grummet J (2017) How to biopsy: transperineal versus transrectal, saturation versus targeted, what’s the evidence? Urol Clin North Am 44:525–534
Yamamoto S, Shigemura K, Kiyota H et al (2015) Essential Japanese guidelines for the prevention of perioperative infections in the urological field: 2015 edition. Int J Urol 23:814–824
Shoji S, Hiraiwa S, Hanada I et al (2020) Current status and future prospective of focal therapy for localized prostate cancer: development of multiparametric MRI, MRI-TRUS fusion image-guided biopsy, and treatment modalities. Int J Clin Oncol 25:509–520
Chiang IN, Chang SJ, Pu YS et al (2007) Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in Taiwan. J Formos Med Assoc 106:929–934
Trujillo CG, Plata M, Caicedo JI et al (2016) Impact of rectal swabs on infectious complications after transrectal prostate biopsy. Urol Int 97:340–346
Seitz M, Stief C, Waidelich R et al (2017) Transrectal ultrasound guided prostate biopsy in the era of increasing fluoroquinolone resistance: prophylaxis with single-dose ertapenem. World J Urol 35:1681–1688
Auffenberg GB, Qi J, Gao Y et al (2018) Evaluation of a needle disinfectant technique to reduce infection-related hospitalisation after transrectal prostate biopsy. BJU Int 121:232–238
Tan WP, Papagiannopoulos D, Latchamsetty KC et al (2019) Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy. Prostate Cancer Prostatic Dis 22:268–275
Singh P, Kumar A, Yadav S et al (2017) “Targeted” prophylaxis: impact of rectal swab culture-directed prophylaxis on infectious complications after transrectal ultrasound-guided prostate biopsy. Investig Clin Urol 58:365–370
Noreikaite J, Jones P, Fitzpatrick J et al (2018) Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 21:153–160
Rosario DJ, Lane JA, Metcalfe C et al (2012) Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ 344:1–12
Petroski RA, Griewe GL, Schenkman NS (2003) Delayed life-threatening hemorrhage after transrectal prostate needle biopsy. Prostate Cancer Prostatic Dis 6:190–192
Raaijmakers R, Kirkels WJ, Roobol MJ et al (2002) Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 60:826–830
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Hiroyoshi Suzuki has received honoraria and/or research grants from Takeda Pharmaceutical Company Ltd, Astellas Pharma Inc, Daiichi Sankyo Company Ltd, Janssen Pharmaceuticals Inc, Pfizer Inc, AstraZeneca, Sanofi, Nippon Kayaku, Bayer Ltd and Taiho Pharmaceutical Company Ltd.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Utsumi, T., Endo, T., Sugizaki, Y. et al. Risk assessment of multi-factorial complications after transrectal ultrasound-guided prostate biopsy: a single institutional retrospective cohort study. Int J Clin Oncol 26, 2295–2302 (2021). https://doi.org/10.1007/s10147-021-02010-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-021-02010-x